Natera (NASDAQ:NTRA) Insider Sells $830,285.88 in Stock

by · The Cerbat Gem

Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider John Fesko sold 3,594 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $231.02, for a total value of $830,285.88. Following the transaction, the insider directly owned 178,081 shares in the company, valued at approximately $41,140,272.62. This trade represents a 1.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

John Fesko also recently made the following trade(s):

  • On Wednesday, January 28th, John Fesko sold 928 shares of Natera stock. The shares were sold at an average price of $237.66, for a total value of $220,548.48.
  • On Tuesday, January 27th, John Fesko sold 784 shares of Natera stock. The shares were sold at an average price of $240.53, for a total value of $188,575.52.
  • On Wednesday, January 21st, John Fesko sold 339 shares of Natera stock. The stock was sold at an average price of $235.00, for a total value of $79,665.00.
  • On Tuesday, January 20th, John Fesko sold 17,806 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $4,179,780.44.

Natera Stock Down 9.7%

NTRA stock traded down $22.07 during midday trading on Wednesday, reaching $205.61. 2,452,176 shares of the company’s stock traded hands, compared to its average volume of 1,059,726. The firm’s fifty day moving average price is $234.95 and its 200-day moving average price is $195.74. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The company has a market cap of $28.44 billion, a price-to-earnings ratio of -89.79 and a beta of 1.64.

Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.26) earnings per share. Analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently made changes to their positions in the business. Legacy Financial Advisors Inc. bought a new position in Natera during the fourth quarter valued at about $330,000. Valeo Financial Advisors LLC bought a new stake in Natera in the fourth quarter worth about $620,000. Colonial River Investments LLC boosted its stake in Natera by 2.3% in the fourth quarter. Colonial River Investments LLC now owns 4,110 shares of the medical research company’s stock valued at $942,000 after acquiring an additional 91 shares during the last quarter. Aubrey Capital Management Ltd grew its position in shares of Natera by 32.1% during the 4th quarter. Aubrey Capital Management Ltd now owns 21,400 shares of the medical research company’s stock valued at $4,902,000 after acquiring an additional 5,200 shares during the period. Finally, LRI Investments LLC grew its position in shares of Natera by 18.2% during the 4th quarter. LRI Investments LLC now owns 683 shares of the medical research company’s stock valued at $156,000 after acquiring an additional 105 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on NTRA. JPMorgan Chase & Co. raised their target price on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Piper Sandler increased their price target on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. UBS Group lifted their price objective on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. TD Cowen reiterated a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

View Our Latest Analysis on NTRA

About Natera

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Read More